Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047500 · ClinicalTrials.gov registry record · Phase 1
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
A Phase 1 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02047500 is a Phase 1 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 19 participants.
The verdict
NCT02047500, a Phase 1 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047500
The ClinicalTrials.gov registry entry for NCT02047500 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02047500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047500 about?
NCT02047500 is a clinical study titled "Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer". This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenoc...
What is the current status of trial NCT02047500?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-01. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02047500?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), TH-302 (DRUG).
Who is sponsoring clinical trial NCT02047500?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.